ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

MOMA Therapeutics launches with $86 million series A to drug molecular machines

by Ryan Cross
April 18, 2020 | APPEARED IN VOLUME 98, ISSUE 15

 

MOMA Therapeutics has launched with $86 million in series A financing, led by Third Rock Ventures, to develop small-molecule drugs against a family of more than 400 proteins—MOMA calls them molecular machines—that use ATP hydrolysis to “generate force and motion.” Examples include DNA helicases and chromatin remodeling proteins, which regulate gene expression. The company has recruited experts in protein biophysics and cryogenic electron microscopy to target molecular machines implicated in cancer and rare diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment